Alcon Reports Q3-2025 Net Sales of $2.6 Billion

Alcon reported Nov. 11 that its Q3-2025 net sales totaled $2.6 billion, a 6 percent increase over $2.4 billion in Q3-2024.

Surgical net sales for implantables, consumables, and equipment/other were $1.4 billion, a 6 percent increase over $1.3 billion in Q3-2024.

The company said implantables growth of 2 percent was driven by the launch of the PanOptix Pro IOL, offset by continued competitive pressures.

Consumables growth of 6 percent reflected improving market conditions and price increases.

Equipment/other growth of 13 percent was fueled by recent equipment launches, including the Unity VCS dual-function cataract/vitrectomy system.

Vision Care net sales for contact lenses and ocular health were $1.2 billion, a 7 percent increase over $1.1 billion in Q3-2024.

Alcon, a Swiss company with US headquarters in Fort Worth, Texas, maintained its full year guidance of $10.3 billion to $10.4 billion.

Santen Generates Quarterly Revenue of $465.6 Million

Japan-based Santen reported Nov. 6 that its revenue for the third quarter of 2025—its fiscal year Q2-2025—was JY69.2 billion ($465.6 million), down 3.4 percent from JY71.6 billion in the same quarter in 2024.

The company said results for the first half of its fiscal year reflected its focus on expanding sales of new and mainstay products, despite the impact of price revisions within Japan’s public National Health Insurance program and adjustments to channel inventory levels.

Santen said it was maintaining guidance from May 2025 of JY294 billion, a 2 percent decrease from JY300 billion in 2024.

Eylea, sold by Santen in Japan under a co-promotion agreement with Bayer, is the company’s highest-selling product, with JP16.3 billion ($109.7 million) in sales in fiscal year Q2-2025, a 15.5 percent decrease from JY19.3 billion in the same quarter in 2024.

Immunocore Posts Q3-2025 Kimmtrak Revenue of $103.7 Million

UK-headquartered Immunocore reported Nov. 6 that its Q3-2025 net revenue from Kimmtrak (tebentafusp) was $103.7 million, a 29 percent increase over $80.2 million in Q3-2024.

Regionally, Kimmtrak net revenue consisted of $67.3 million in the US, $33.5 million in Europe, and $2.9 million in other international regions.

The company said revenue growth was due primarily to increased volume in the US and Europe and global expansion.

Kimmtrak, a treatment for unresectable or metastatic uveal melanoma, is now approved in 39 countries and has been launched in 28.

STAAR Surgical Reports Q3-2025 Revenue of $94.7 Million

STAAR Surgical, of Lake Forest, California, reported Nov. 5 that its Q3-2025 net sales totaled $94.7 million, up 6.9 percent over $88.6 million in Q3-2024.

The Q3-2025 total included $25.9 million related to a previously disclosed ICL shipment in December 2024 that was subject to extended payment terms and paid in full in Q3-2025.

STAAR said it saw Q3-2025 net sales growth outside China of 7.7 percent, partially offset by lower new orders from distributors in China.

The company noted that sales for the first three quarters of 2025 were lower than the prior year period as distributors in China reduced their inventory by approximately $80 million to $85 million instead of purchasing new product from the company.

In addition, STAAR has now postponed until Dec. 19 its special meeting of shareholders to vote on Alcon’s acquisition of the company.

Harrow Generates Q3-2025 Revenue of $71.6 Million

Harrow, of Nashville, Tennessee, reported Nov. 10 that Q3-2025 revenue was $71.6 million, a 45 percent increase over $49.3 million in Q3-2024.

Vevye revenue in Q3-2025 was $22.6 million, up from $5.2 million in Q3-2024 and accounting for 32 percent of company revenue, while Iheezo revenue was $21.9 million, up from $12.9 million in Q3-2024 and representing 31 percent of total revenue.

Harrow lowered its 2025 revenue guidance to $270 million to $280 million from more than $280 million in August, reflecting underperformance by Triesence and the company’s Rare & Specialty Portfolio. Harrow relaunched Triesence in the US in October 2024 after obtaining US rights in 2023. The preservative‑free synthetic is US approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

Harrow CEO Mark Baum said he remains bullish on Triesence based on several positive trends. Triesence’s Q3-2025 unit sales grew 67 percent sequentially over Q2-2025.

RxSight Posts Q3-2025 Revenue of $30.3 Million

RxSight reported Nov. 5 that its Q3-2025 revenue was $30.3 million, a 14 percent decrease from $35.3 million in Q3-2024.

The Aliso Viejo, California, company said it sold 25 Light Delivery Devices (LDDs), a 68 percent decline compared with 78 in Q3-2024, expanding the installed base to 1,109 LDDs.

RxSight also sold 26,045 Light Adjustable Lenses (LALs), a 6 percent increase over 24,554 lenses sold in Q3-2024.

The company said it had realigned its US commercial organization during the third quarter, integrating clinical and sales teams to help resume growth in LAL procedures with deeper LAL practice integration. It also appointed an executive vice president, international, to lead RxSight’s international commercial strategy and execution.

The company narrowed its full-year 2025 revenue range to $125.0 million to $130.0 million, compared with the prior range of $120.0 million to $130.0 million.

Sight Sciences Reports Q3-2025 Revenue of $19.9 Million

Sight Sciences, of Menlo Park, California, reported Nov. 6 that its Q3-2025 revenue was $19.9 million, a 1 percent decrease from $20.2 million in Q3-2024.

Surgical glaucoma accounted for $19.7 million, a 6 percent increase over $18.6 million in Q3-2024, which the company said was primarily due to increased ordering accounts and average selling price, partially offset by lower account use from MAC coverage restrictions on the performance of multiple MIGS procedures in combination with cataract surgery.

Sight Sciences’ dry eye revenue was $0.2 million, down from $1.5 million in Q3-2024. The company reiterated from previous earnings reports that the expected decline was primarily due to fewer new SmartLids sales, which was a result of the company’s focus on achieving reimbursed market access for TearCare procedures.

ANI Generates Q3-2025 Iluvien Revenue of $16.6 Million

Baudette, Minnesota-based ANI Pharmaceuticals reported Nov. 7 that its Q3-2025 revenue for Iluvien was $16.6 million.

Q4-2024 was the first full quarter of ANI’s ownership of Iluvien and Yutiq following ANI’s acquisition of Alimera Sciences in September 2024.

ANI has stopped marketing Yutiq now that Iluvien has added Yutiq’s labeling of chronic non-infectious uveitis affecting the posterior segment of the eye to its initial labeling of diabetic macular edema.

ANI said net revenue for Iluvien was pressured due to further impact from continued reduced access for Medicare patients (due to a lack of funding for third-party co-pay assistance programs such as the Good Days charity). Another factor weighing on revenue was use of the remaining Yutiq units at physician offices.

ANI breaks out its 2025 revenue guidance by product. The company’s 2025 guidance for Iluvien and Yutiq is $73 million to $77 million, down from $87 million to $93 million in August.

ANI also sells purified Cortrophin gel, whose eight indications include ophthalmic uses. The company does not break out Cortrophin gel sales by segment.

Lensar Posts Q3-2025 Revenue of $14.3 Million

Lensar, of Orlando, Florida, reported Nov. 6 that its Q3-2025 revenue was $14.3 million, a 6 percent increase over $13.5 million in Q3-2024.

The company said growth was primarily due to increased procedure volume worldwide. Q3-2025 procedures totaled 46,811, up 11 percent over 42,231 in Q3-2024.

Lensar placed 18 Ally systems in Q3-2025, increasing the installed base to about 185, a 77 percent increase over the installed base in Q3-2024.

Alcon’s acquisition of Lensar, announced in March, is now expected to close in Q1-2026, subject to customary conditions, including regulatory clearance and approval by Lensar shareholders.

Iridex Reports Q3-2025 Revenue of $12.5 Million

Iridex, of Mountain View, California, reported Nov. 11 that its Q3-2025 revenue was $12.5 million, an 8 percent increase over $11.6 million in Q3-2024.

The laser company said revenue for its Cyclo G6 product family was $3.5 million, a 13 percent increase over $3.1 million in Q3-2024.

Iridex sold 14,900 Cyclo G6 probes compared with 13,600 in Q3-2024.

The company sold 30 Cyclo G6 Glaucoma Laser Systems, compared with 26 in Q3-2024.

Retinal product revenue in Q3-2025 was $6.7 million, a 4 percent increase over $6.5 million in Q3-2024.

More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

Topics of Interest

Products of Interest